Viking Touts Promising Phase I Weight Loss Data for Obesity Pill Candidate
Jefferies analyst Roger Song in an investor note said that Viking Therapeutics’ readout for its investigational therapy VK2735 exceeded expectations, with “class-leading” weight loss. Patients on 100-miligram doses of the pill lost 8.
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, ...
AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an ...
It also has another pill, amycretin ... said it expects CagriSema and amycretin to achieve better weight loss results than Wegovy. Lilly is also developing the GIP/GLP-1/glucagon receptor ...
Oral GLP-1 drug in study led to average weight loss of 8.2% in a month at a 100 ... NOVO.B) and Eli Lilly (LLY), although the existing drugs on the market have to be injected rather than taken ...
AstraZeneca (AZN) said Monday at the ObesityWeek conference in San Antonio, Texas that its experimental obesity pill was well-tolerated by ...
Obesity pill data released by Viking Therapeutics Inc and AstraZeneca Plc at a big conference foreshadowed an increasingly ...
Shares of Viking Therapeutics (NASDAQ:VKTX) jumped 22% Monday morning after the biotech firm reported promising results for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback